» Articles » PMID: 2825934

A 6-hour Human Parathyroid Hormone (1-34) Infusion Protocol: Studies in Normal and Hypoparathyroid Subjects

Overview
Specialty Pathology
Date 1987 Nov 1
PMID 2825934
Citations 2
Authors
Affiliations
Soon will be listed here.
Abstract

Parathyroid hormone (PTH)-resistant states are usually diagnosed by the failure of an acute PTH injection to elicit a rise in urinary cAMP and phosphate or, less commonly, by the failure of repeated PTH injections to raise serum calcium. We have established a 6 hour infusion of human PTH (1-34) which identifies PTH-resistant hypoparathyroid subjects on the basis of serum 1,25-dihydroxyvitamin D (1,25(OH)2D) and calcium responses. 1,25-Dihydroxyvitamin D levels increased by at least 58 pmol/liter and serum calcium by at least 0.1 mmol/liter in PTH-responsive hypoparathyroid subjects (n = 6), whereas in pseudohypoparathyroid subjects (n = 5) these levels rose by less than 22 pmol/liter and 0.06 mmol/liter respectively. The responsiveness of urinary phosphate excretion, expressed as the renal threshold phosphate concentration (TmPO4/GFR), to PTH also clearly separated the pseudohypoparathyroid patients from the other subjects. Differences in urinary calcium responses were observed though this parameter was less reliable in the identification of individual PTH-resistant or PTH-sensitive hypoparathyroid patients. Nephrogenous cAMP did not discriminate between groups when this protocol was used. This test has the potential to facilitate and extend the classification of PTH-resistant states.

Citing Articles

(1-34) Parathyroid hormone infusion acutely lowers fibroblast growth factor 23 concentrations in adult volunteers.

Gutierrez O, Smith K, Barchi-Chung A, Patel N, Isakova T, Wolf M Clin J Am Soc Nephrol. 2012; 7(1):139-45.

PMID: 22246283 PMC: 3265347. DOI: 10.2215/CJN.06240611.


Antiidiotypic PTH antibodies as a cause of elevated immunoreactive parathyroid hormone in idiopathic hypoparathyroidism, a second case: another manifestation of autoimmune endocrine disease?.

McElduff A, Lackmann M, WILKINSON M Calcif Tissue Int. 1992; 51(2):121-6.

PMID: 1422950 DOI: 10.1007/BF00298499.

References
1.
Furlong T, Seshadri M, Wilkinson M, Cornish C, Luttrell B, Posen S . Clinical experiences with human parathyroid hormone 1-34. Aust N Z J Med. 1986; 16(6):794-8. DOI: 10.1111/j.1445-5994.1986.tb00040.x. View

2.
Slovik D, Daly M, Potts Jr J, Neer R . Renal 1,25-dihydroxyvitamin D, phosphaturic, and cyclic-AMP responses to intravenous synthetic human parathyroid hormone-(1-34) administration in normal subjects. Clin Endocrinol (Oxf). 1984; 20(4):369-75. DOI: 10.1111/j.1365-2265.1984.tb03432.x. View

3.
Yamaoka K, Seino Y, Ishida M, Ishii T, Shimotsuji T, Tanaka Y . Effect of dibutyryl adenosine 3',5'-monophosphate administration on plasma concentrations of 1,25-dihydroxyvitamin D in pseudohypoparathyroidism type I. J Clin Endocrinol Metab. 1981; 53(5):1096-100. DOI: 10.1210/jcem-53-5-1096. View

4.
Elrick H, Albright F, Bartter F, FORBES A, REEVES J . Further studies on pseudo-hypoparathyroidism: report of four new cases. Acta Endocrinol (Copenh). 1950; 5(3):199-225. DOI: 10.1530/acta.0.0050199. View

5.
Larkins R, MacAuley S, Rapoport A, Martin T, Tulloch B, Byfield P . Effects of nucleotides, hormones, ions, and 1,25-dihydroxycholecalciferon on 1,25-dihydroxycholecalciferol production in isolated chick renal tubules. Clin Sci Mol Med. 1974; 46(5):569-82. DOI: 10.1042/cs0460569. View